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Abstract
Most studies that follow subjects over time are challenged by having some subjects who dropout.
Double-sampling is a design that selects, and devotes resources to intensively pursue and find a
subset of these dropouts; then uses data obtained from these to adjust naïve estimates, which are
potentially biased by the dropout. Existing methods to estimate survival from double-sampling
assume a random sample. In limited-resource settings however, generating accurate estimates
using a minimum of resources is important. We propose using double-sampling designs that
oversample certain profiles of dropouts as more efficient alternatives to random designs. First, we
develop a framework to estimate the survival function under these profile double-sampling
designs. We then derive the precision of these designs as a function of the rule for selecting
different profiles, in order to identify more efficient designs. We illustrate using data from a
United States President’s Emergency Plan for AIDS Relief (PEPFAR)-funded HIV care and
treatment program in western Kenya. Our results show why and how more efficient designs
should oversample patients with shorter dropout times. Further, our work suggests generalizable
practice for more efficient double-sampling designs, which can help maximize efficiency in
resource-limited settings.
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1 Introduction
In most studies that follow subjects over time, some subjects discontinue their contact with
the investigators (also called patient dropout). Double-sampling is a design that selects a
subset of the dropouts and devotes enough resources to intensively pursue and find their
information. When survival is the target of estimation, the methods that are needed to
analyze the double-sampled data are different and more demanding than those for simpler
designs; see, for example, Frangakis and Rubin [1], Baker, Wax, and Patterson [2], and An
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et al. [3]. Most such designs so far assume that the double-sampled subset is a random
sample of all the dropouts.
In most settings, maintaining high precision of the estimates for low cost is a serious
concern. For example, the United States President’s Emergency Plan for AIDS Relief
(PEPFAR, www.pepfar.gov), an international response effort initiated in 2003 with a $15
billion budget and renewed in 2008 for five additional years with a $48 billion budget,
works in part to provide antiretroviral therapy (ART) to HIV-infected individuals in
resource-poor countries, primarily in sub-Saharan Africa. Key goals of this effort include
increasing access to treatment, and ultimately improving survival of HIV-infected patients
under care provided by its partners. Congress mandates, as part of the PEPFAR funding,
monitoring and evaluation of the funded programs. Therefore it is important, in order to
monitor the program, that methods of evaluating survival optimize precision subject to cost
and sampling constraints. A natural question then is, instead of double-sampling at random,
can we oversample certain profiles of individuals in order to gain efficiency?
There are several reasons why double-sampling based on patient characteristics is important
for gaining efficiency. First, it is well-known that patient characteristics (e.g., CD4 count)
can predict survival time in HIV patients [4, 5]. Second, imagine oversampling individuals
who have been under observation for a short period (i.e., they have short dropout times).
These individuals expectedly provide more information towards the target estimand, beyond
what we would have without double-sampling them, relative to individuals with long
dropout times. With the latter group, it is more likely they have passed the time for which
survival estimates are of interest. We refer to this selective double-sampling as “profile”
double-sampling.
We develop a framework that characterizes the role of different such profile double-
sampling designs for inference on survival data. Using this framework, we obtain insightful
expressions of precision as functions of the design. By studying classes of double-sampling
designs, we obtain profile designs that have improved precision and suggest generalizable
practice.
In Section 2, we briefly describe the circumstances motivating this work and review the
double-sampling design for survival data. In Section 3, first, we develop a likelihood
framework that allows survival estimation from a double-sample based on individual
information, and focus on a maximum-likelihood based approach. In Section 4, we derive
the precision of the maximum likelihood estimator (MLE) for a given profile double-
sampling design, which allows comparison of different double-sampling designs. In Section
5, we apply our methods in the evaluation of a large HIV care and treatment program in
western Kenya, and identify a profile double-sampling design that is considerably more
efficient than simple or ad hoc random double-sampling designs. Section 6 concludes with a
discussion.
2 Profile Double-Sampling Design and Goal
The design is motivated by data assembled for a cohort of 8,977 HIV-infected adults who
entered the Academic Model Providing Access to Healthcare (AMPATH), a comprehensive
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HIV care and treatment program located in western Kenya, between January 1, 2005 and
January 31, 2007. The goal here is to estimate the survival distribution of these individuals
after their enrollment in the program, P(T > t). The care and treatment program and the
patient double-sampling (“outreach”) efforts are described in detail elsewhere [3, 6–8]. For
our purpose we can summarize these by viewing the design as having two phases.
In Phase 1 of the design, monitoring proceeds with standard effort (i.e., no double-
sampling). Here, we observe the entry date Ei for all patients. If standard monitoring
continued indefinitely, we would observe that some patients discontinue contact from the
standard monitoring: we call these patients true dropouts and indicate them by Ri = 0, and
denote their time from enrollment (i.e., time 0) to dropout by Li. On the other hand, some
patients would be true non-dropouts, whom we indicate by Ri = 1 and for whom Li is
undefined. Further, patients may be subject to administrative censoring. That is, if the time
of analysis is “Now” (Emax), then the time between enrollment Ei and Emax is known as the
administrative censoring time, and denoted by Ci. Patients who have Ci < Ti are
administratively censored and are indexed by Δi = 0; otherwise patients are indexed by Δi =
1. It is important to note that administrative censoring allows only a subset of the true
dropouts (Ri = 0) to be observed and known as true dropouts, whereas for the others, their
true dropout status (that they would dropout later) is masked by administrative censoring. A
person observed to dropout is denoted by  and one observed to not dropout is
denoted by , and could either have Ri = 0 or Ri = 1.
Double-sampling efforts introduce a second phase in the design. In Phase 2, investigators
select a subset of the observed dropouts , called a double-sample, by using baseline
characteristics Zi and possibly dropout time Li, and devote enough resources to follow this
subset and find either their survival time or that they are alive until Emax, i.e., we find (Xi ≡
min(Ti, Ci), Δi). We indicate by Di = 1 those who are double-sampled, and Di = 0 otherwise.
Expressed statistically, this Phase 2 design structure adds the following important condition:
Condition 1: Designed Profile Double-Sampling
Among observed dropouts, the observed covariates Zi and dropout time Li include the
variables involved in the selection and successful recovery of those to be double-sampled.
We can express this by stating that, among observed dropouts and after we condition on
Profilei = (Zi, Li), selection for and recovery by double-sampling is independent of survival
and entry times, or equivalently,
Note that Li is measured after entry time, but can be an important factor for precision of the
design as discussed in the introduction. Because the typical survival data (Xi, Δi) are
functions of (Ti Ci), it is an immediate implication of Condition 1 that, conditional on the
observed covariates, selection for and recovery by double-sampling is independent of (Xi,
Δi): Di ⊥ (Xi, Δi) ∣ ( , Profilei).
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Based on the above, the choices the investigator has for a particular profile double-sampling
design are the time of analysis Emax, and the rule for double-sampling given dropout and
individual characteristics,
(1)
For a given pattern of entry dates, Emax determines the distribution of administrative
censoring times, P(C∣Z). We consider the time of analysis (Emax) fixed and search for best
designs of the form described in equation (1).
Information from these phases can be classified into patient characteristics (i.e., Ei, Ti, Ri, Li,
Zi; Figure 1), design characteristics (Emax, Di, Profilei; Figure 1), and a product of both
patient and design characteristics (Ci, , Xi, Δi; Figure 1); and can be used to estimate the
cohort survivor function P(T > t).
Note that Ri and  can be different. Ri is a characteristic of the patient, and both Ri and Li
are missing if the person is administratively censored. On the other hand , although
observed, is determined by both the patient characteristics Ri and Li and by the design’s time
of analysis Emax, namely whether Li < Emax–Ei. Thus the concept of true dropout behaviour,
Ri and Li, is central for separating patient from design characteristics.
For estimability, since T is still missing for the administratively censored patients, we invoke
the following condition:
Condition 2: Time homogeneity
Conditional on the observed covariates, entry time (equivalently, administrative censoring
time) is independent of survival time and of potential dropout status. We can express this as:
Ci ⊥ (Ti, Ri, Li) ∣ Zi, since entry times Ei = Emax–Ci.
We note that Condition 2 includes the typical conditional independence of administrative
censoring, Ci ⊥ Ti ∣ Zi. Moreover, Condition 2 is plausible within blocks of time if,
conditional on observed covariates such as gender, baseline CD4 count, baseline World
Health Organization (WHO) stage, clinic type, and treatment status, we assume no secular
trends in survival or true dropout behavior. Such an assumption could not be expressed in
terms of observed dropout status, which depends not only on patient characteristics but also
on design characteristics such as the time of analysis (Emax).
3 Estimation for a given design
A useful intuition for how appropriate estimation can work and for what can go wrong with
a standard approach is provided from the simple case where double-sampling does not
depend on patient data other than that a patient has been an observed dropout. Then, the
“typical survival information”, (Xi, Δi), is missing at random [9] within the stratum of
observed dropouts (Robs = 0). In that case, for the double-sampled individuals, for whom the
data (Xi, Δi) are recovered, the only remaining source of missing survival times is the
possible administrative censoring by Ci. Under Conditions 1 and 2 with no covariates, a
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consistent nonparametric estimator can then be constructed by, in principle, scaling up the
distribution of (Xi, Δi) from the double-sampled patients to the set of all dropout patients.
This scaling up in practice is achieved by mixing estimates of the two crude hazard
functions of observed non-dropouts and double-sampled dropouts [1]. In contrast, a standard
approach that would mix the two Kaplan-Meier estimators based on those two strata is in
general inconsistent even if there is no covariate necessary to stratify in Conditions 1 and 2.
This is because the strata of observed dropouts/non-dropouts are functions not only of the
inherent patient characteristic (Ri, Li, Ti) but also of the design characteristics (Section 2).
This creates a dependence between administrative censoring Ci and survival Ti within the
observed strata Robs even under Conditions 1 and 2, and so invalidates the within-strata
Kaplan-Meier estimators. Analogous arguments hold if we use a double-sampling design
that depends on discrete levels of baseline covariates, where a consistent nonparametric
MLE from simple data still exists [3].
When the design depends on a multitude of data or continuous patient history data, a
nonparametric MLE is not possible. In this case, one important task is to find and use the
MLE of a plausible parametric model. Alternatively, one can find estimators that use the
inverse of the double-sampling probabilities and are based on a semi-parametric framework,
e.g., [10]. The latter approach also requires the use of likelihood estimators because (a) the
augmentation part needed to construct locally efficient semi-parametric estimators is itself
derived from a general likelihood submodel [11]; and (b) the approach of inverting
probabilities does not work for designs that exclude from the double-sampling certain
patients who are practically impossible to find. Therefore, for all the above approaches, it is
central to first find the likelihood of data from designs under Conditions 1-2. So we present
the discussion on design efficiency from a likelihood perspective. Perspectives based on a
semi-parametric approach will be studied in future work.
The target estimand, the survivor function, can be expressed through the chain of conditional
distributions (here T, R, Z, L represent the random variables corresponding to their
respective individual counterparts Ti, Ri, Zi, Li):
When S(t ∣ Z, θ) := P(T > t ∣ Z, θ) is estimated by , we can estimate the cohort
(marginal) survivor function S(t ∣ θ) in our original goal as a function of t, by the empirical
average over all n individuals:
(2)
In order to estimate S(t ∣ Z, θ), it is important to find how the likelihood depends on arbitrary
(nonparametric) distributions of the observed data. To write the likelihood of the observed
data in Section 2, which we denote collectively by Datai for each person, first note that the
covariates Zi and administrative censoring time Ci are observed for all people. Then, it is
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useful to classify the patients into the following five types described below and displayed in
Figure 1:
a. a non-dropout who dies on observation ( , Δi = 1), for whom we also observe
survival time Ti and for whom Li is undefined;
b. a non-dropout alive at time of analysis ( , Δi = 0), for whom Li is either
undefined or missing according to whether they are true non-dropouts or true
dropouts, respectively;
c. a dropout who is double-sampled and dies on observation ( , Di = 1, Δi = 1),
for whom we also observe the dropout and survival times Li, Ti;
d. a dropout who is double-sampled and is alive at the time of analysis ( , Di =
1, Δi = 0), for whom we also observe dropout time Li; or
e. a dropout who is not double-sampled ( , Di = 0), for whom we also observe
dropout time Li.
It follows from the above that, if we let θ denote the vector of parameters, the observed
likelihood for an individual is given by:
(3a)
(3b)
(3c)
(3d)
(3e)
where the lettering (a)-(e) corresponds to the types of patients described above and displayed
in Figure 1. In the above expressions, we use, for example, P(Ti, Δ = 1, …) to mean P(Ti∣Δi
= 1, …) · P(Δi = 1, …), i.e., the likelihood contribution of an individual i who is observed to
die and whose survival is Ti and has other data …, which is the product of a density for Ti
(given Δi = 1, …) and the likelihood of (Δi = 1, …).
The above expression is important for two purposes. First, it indicates how we can develop
an E-M algorithm by capitalizing on the fact that (3b) is a mixture of terms for true dropouts
(R = 1) and true non-dropouts (R = 0) (see supporting web files).Further, it is important for
identifying a more efficient design, as shown in Sections 4 and 5. Notice that, once data are
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observed, the design components e() in (3c), (3d) and (3e) are ignorable [12] for likelihood
estimation. These components are important, however, for estimating precision of candidate
designs to be implemented on a larger scale, and thus will play a role in Sections 4 and 5.
4 The relation of precision to profile double-sampling designs
In order to facilitate the study of more efficient designs, it is useful to regroup the terms of
the likelihood into two parts - the part that is contributed by all individuals from Phase 1,
and the additional part that is contributed from the double-sampled individuals from Phase
2. We can do this by regrouping expression (2) as
(4)
plus terms not depending on θ, where the above can be shown to be expressable in terms of
the patient characteristics, as:
(5)
(6)
The information matrix of the MLE of θ, defined as the expectation of the negative second
derivative of (4), will depend on who is sampled, Di = 1, only through the second term of
(4), given in (6). From Section 2, “who is double-sampled” is characterized by the rule of
selection e(Profilei) where Profilei = (Zi, Li), the variables used to select double-samples. So
the expectation of the negative second derivative of (4) depends on the rule e(·) as well as θ,
and is denoted by I(e(·), θ). It is easy to show (see supporting web files) the following useful
results:
Result 1
The information of the MLE is related to the design e(·) by:
where
(7)
where 
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The design e(), through the above precision for θ, determines the precision for estimating
the target estimand, the cohort survival curve S(t). In the supporting web files, we show the
following:
Result 2
The large sample distribution of the estimator (2) is given by :
where V(e(·), θ) = Eθ{Sθ(t ∣ θ)’} I(e(·), θ)−1 Eθ{Sθ(t ∣ θ)} + varθ{S(t ∣ Zi, θ)} and Sθ(t ∣ θ) =
∂S(t ∣ θ)/∂θ, and  represents convergence in distribution as n → ∞ for fixed t.
Note that the variance V is controlled by the design e() only through I(e(), θ), hence, from
Result 1, only through  (e(·), θ), given in (7). We call a design that has already
been implemented and in particular, in which a double-sample has been obtained via, for
example a random double-sample design where epilot(·) = constant, a “pilot design.” In a
pilot design, the first expectation term in (7) can be estimated by replacing e(Profilei) with
Di and δ(Profilei, θ) with δi(θ), where
(8)
and taking the empirical average over all observed dropouts; and  can be
estimated by the observed proportion of dropouts in the total sample. We refer to a design
that has not yet been implemented, but is under consideration as ecandidate(·), a “candidate
design.” We can estimate (7) for a candidate design using data from the pilot design by:
whose expectation equals the expression in (7), and where δi(θ) is as defined in (8). In
summary, to estimate (7) using data from a pilot design,
(9)
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Based on the above, then, V can be estimated by:
(10)
where  is as in (9), and f, g, ,  are defined as:
5 Identifying more efficient designs in practice
5.1 General Procedure
In practice the researcher can use the above methods in the following way to identify a more
efficient design strategy.
1. Estimate the distribution of patient characteristics from pilot data using a simple
design. Implement the pilot design on a modest scale with a convenient, perhaps a
random, double-sampling design, i.e., e(·) =constant. From these pilot data,
estimate a model for the patient characteristics T, L, R. Obtain the MLE of the
parameters, , of such a model.
2. Decide on a class of designs to search. Decide on a set of candidate designs {e} for
the larger scale implementation. This set is usually dictated by administrative
reasons and so it often fixes a maximal allowable recruitment window (P(C ∣ Z)).
3. Identify a more efficient design. Estimate the best design e(Profilei) from the set of
candidate designs {e}. The best design is the rule e(·) which minimizes the variance
V(e(·), θ). The best design can be estimated, using the pilot data, as the design that
minimizes the estimated variance  in (10).
A larger-scale follow-up can then be conducted according to the more efficient design. After
the data have been collected, any method of survival estimation that is appropriate for use
with double-sampled data can be adopted (e.g., as described in [3] or in Section 3).
5.2 Illustration: Designing PEPFAR program evaluations
In this section, we illustrate identifying a more efficient design using a pilot design from the
AMPATH cohort. We use these pilot data to identify a design that uses the patient profiles
to more accurately estimate the survival function in larger scale studies with similar
characteristics.
1. Estimate the distribution of patient characteristics from AMPATH pilot data using
a simple design. We used the AMPATH cohort [3] as pilot data, and considered,
based on input from our collaborators for which variables they believe to be
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predictive of dropout, the following baseline covariates Z: gender, baseline CD4
count, baseline WHO stage, indicator of urban versus rural clinic, and ART start
status. We specified logit(R∣Z) as ; P(T∣R = 1, Z) as log-normal
; P(L∣R = 0, Z) as log-normal ; and P(T∣R = 0, L,
Z) as a log-normal , left-truncated at L (i.e., T > L). Based
on these variables and models, we formulated and used an EM algorithm [13] to
estimate the MLE of the parameters. The EM requires specification of the complete
data log likelihood (see Appendix). Note that other data distribution models could
be explored, so long as software exists to easily fit these models. We in turn
estimated the 1-year survival probability at 0.86 (se=0.008).
2. Search within the class of designs based on dropout time and predictor for dropout.
We consider the variables Profilei for selecting whom to double-sample in the
AMPATH cohort [3] to be a predictor, P, for dropout and the actual time for
dropout L. The former, P, is the linear predictor from a Cox model for dropping out
based on the baseline covariates (listed above), with advanced WHO status and
male gender being the primary risk factors of patient dropout [8]. Thus, P serves as
a single-number summary of factors predictive of dropout.
In practice to search for a more efficient design, it may be more convenient and
insightful to consider double-sampling from discrete groups. Such discretization
leads to a convenient estimator of the variance given in Result 2. Moreover,
studying the variation in precision across discretized groups can yield generalizable
suggestions on how to increase precision. We consider double-sampling within the
discretized groups formed by cross-classifying tertiles of the linear predictor for
removal (P ) and the tertiles of dropout time (L) (Table 1(a)). The idea is to allow
for oversampling of certain groups, but random sampling within groups.
A total of 3528 patients were observed dropouts. We distributed those dropouts in
the cross-classification of L and P so as to classify approximately 390 patients
(11%) in each of the nine cells. A total of 621 dropouts were double-sampled. Let
 denote the number of dropouts that the pilot design double-samples from cell
k, k = 1, 2, … , 9. It is interesting to note that in fact, even the original design
deviates from being independent of the observed predictors P, L. This deviation
does not matter for the validity of estimation of the parameters using our methods,
as the latter account for any dependence of the double-sampling on the observed
predictors. Denote by nk the number of dropouts that a candidate design double-
samples from cell k, k = 1, … , 9 (Table 1(a)-(b)).
3. Identify a more efficient design. We wish to find the allocation n1, …, n9 that
minimizes the variance of the survival estimator (2), subject to having a fixed total
number n(D=1) of patients to double-sample, i.e., 
To do this, we first estimate the components of the variance expression (10). Then, for a
fixed double-sample size n(D=1) = 621, we minimize the estimated variance (10) over
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possible designs e(·) characterized by Table 1(a). Using the expression of the information
I(e(·), θ) from Result 1, it is easy to show that this is equivalent to finding the number of
people, nk, to double-sample from each profile cell k, in order to minimize over all possible
designs {nk} the variance expression
such that the eigenvalues of  are positive, and where f, g,  can be
calculated from the pilot study based on the definitions in (10), and  can be
calculated via:
such that ∑k nk = n(D=1), and
We impose the condition on the eigenvalues to ensure that the information matrix is positive
definite.
We identified the more efficient design shown in Table 1(c) using a Gauss-Seidel-type
algorithm to search the design space. In the more efficient design, we observe an
oversampling of individuals with short dropout times (L). This confirms the intuition
expressed in the Introduction. Also, among individuals with higher risk for dropout in Phase
1, the more efficient design suggests double-sampling both individuals with short and
medium dropout times (L). This can be explained by the smaller observed variability of L in
these higher risk categories, and so the need to better inform on the regression relations by
ensuring that we include in the design enough variability in L.
Although this more efficient design has not yet been implemented, we estimate, using the
pilot data, that the potential gain in efficiency associated with the more efficient design
compared to the original design is 37% (=100(1 – 4.5/7.1) from Tables 1(b)-(c)). In other
words, the follow-up can save 37% of resources for the same precision. This increased
efficiency is particularly important when program monitoring and evaluation resources are
scarce as it is the case in most PEPFAR-funded HIV care and treatment programs. It is
worth noting again that in the original design, among individuals with similar dropout times,
the observed double-sampling was not random; this suggests that the potential efficiency
gains for an more efficient design relative to a truly random design may be greater than what
we estimate.
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5.3 Results based on sensitivity considerations
In order to understand better the above results, we conducted a number of additional
analyses. First, within the context of the model of Section 5.2 step 2, we changed the
predictor set for estimating the linear predictor P of dropout, by removing the ART start
status as this had not been decisively important in predicting time to dropout (hazard
ratio=1.21, se=0.21, p=.35). Analyses with this new risk index are reported in column
“without ART” in Table 2. Second, to examine the influence of the parametric functional
forms of the model of Section 5.2 step 1, we estimated the 1-year mortality and standard
error of the estimate using the nonparametric estimator of [3, 14] that adjusts for different
probabilities of double-sampling in each of the nine levels of the designs in Table 1. These
analyses are reported in the rows “nonparametric (estimate, se) in Table 2 for the original
design. Third, we also estimated the predicted more efficient design and the estimated
variance it would produce for the 1-year mortality if using the modified risk index in which
ART is excluded. This design is reported in Table 1(d) and its resulting standard error is
reported in the row of “predicted more efficient design” of Table 2 for the parametric
estimator (the nonparametric estimator cannot be applied in the predicted more efficient
designs because some of its cells are empty).
The parametric MLE of the 1-year mortality estimate when not using ART in the risk index
was 13.98% (se=0.81%) essentially the same as when using ART in the risk index (estimate
13.94%, se=0.84%). The nonparametric estimates were 11.59% (se=0.88%) and 11.64%
(se=0.85%) when not using versus when using ART in the risk index, respectively. These
are close to the parametric estimates, especially considering that if, instead of changing to
parametric estimates, one had changed instead the design to one without double-sampling
(with a standard survival analysis where dropouts are censored at time of dropout), the 1-
year mortality estimates are dramatically smaller (1.7%, [3]). Finally, the more efficient
design when not using ART versus using using ART in the risk index (Table 1 (d) vs. (c))
carry the same message of the need to focus double-sampling to patients with short and
medium dropout times; the variance of the 1-year mortality for these two designs are very
close to each other.
6 Discussion
The potential utility of imbalanced double-sampling designs for survival estimation has been
indicated earlier ([1, Sec 5, par 3]; and [15, Sec. 2]), but without an explicit search for good
such designs. We have shown how to characterize the precision of a profile double-sampling
design, and how to use a pilot study to find a better design that saves resources which can be
allocated for the treatment of additional patients. Based on a parametric likelihood approach,
better designs were ones that primarily oversample patients who have short dropout times or
have slightly longer L but higher risk for dropout P and either undersample or completely
avoid pursuing patients with long dropout times, regardless of the risk of dropout. This
strategy, in addition to being intuitive in the statistical sense, provides a reasonable means to
determine which dropouts to locate in a preferential fashion. Some of the factors which
increase dropout risk, particularly advanced WHO status, are also directly related to the risk
of mortality. This is because the mortality rate among dropouts is extremely high [3]. A
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recent meta-analysis of a number of HIV care and treatment programs, which perform
outreach, found up to 87% of located dropouts were deceased [16]. In addition, men have
higher dropout rates and consistently worse outcomes compared to women [6]. Thus,
oversampling early dropouts and patients at high risk for dropout and poor clinical outcome
makes sense, as such a sampling strategy performs outreach on some of the most vulnerable
patients in a program.
The estimates of mortality and the estimate of better designs depend on a number of
assumptions. First, Conditions 1 and 2 are about the structure of the problem regardless of
parametric assumptions. Condition 1 is plausible because we have elicited from the field
investigators information about how double-sampling is actually being conducted; Condition
2 is plausible within small time windows where concerns about trends of the epidemic are
not substantial. Second, there are dimension reduction and parametric assumptions. Both in
earlier work without using dropout time information [3] and also here, in Section 5.3, using
dropout time information, we have found that using a nonparametric versus a parametric
approach, did not materially change the mortality estimates; and that small changes to the
specification of a risk index for dropout provided similar messages about how to improve
the design. This provides evidence that the parametric model closely reproduces the
nonparametric results and that the design results are relatively robust to how a risk index for
dropout is summarized.
Here we considered a fixed double-sample size, and identified a more efficient allocation
under this constraint. Alternatively, we could also consider a target precision, and identify
the size of the sample and an allocation which minimizes the overall double-sample size or
cost. Finally, we note the importance of having a representative double-sample. There is
evidence that a representative double-sampling cohort is realistically possible in the setting
we consider ([14], [17]). Of course, the larger the representative sample, the more precise
the parameter estimates. So we hope that the utility of this design can lead to large
scalability.
In our framework, we introduced the concept of a “true dropout” (R). Because the true
dropout is a patient characteristic (i.e., independent of the design’s follow-up), its modeling
(i.e., what we learn from it) is expected to be more generalizable to other designs (and
communicable to researchers of different studies) than the modeling of the observed
dropout, which does depend on the design (and could have different meanings across
different studies.) For example, the concept of true dropout and L for such a person is
important if we were to also treat “Now” (i.e., the longest follow-up) as a possible design
factor to manipulate. This remains for future work, but the current framework holds for both
that and this current work.
In addition to mortality as a goal, one might also wish to assess a program with the
composite event of “death or dropout”. Using standard empirical process (nonparametric)
estimation for competing risks, we estimated that 41.9 % (se=0.6%) of the patients either die
or dropout after 1 year of follow-up (P(Ti ≤ 1, Ri = 1) + P(Li < 1, Ri = 0)); and that only
1.3% (se=0.1%) die by year 1 without being lost from observation. Note that both of these
probabilities are estimated without the information from double-sampling. The 41.9% rate of
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the composite event of death or dropout would be appropriate in a setting where dropout
would mean almost certain death. This is not the case here, however, where the 13%
mortality (based on the double-sampling information) is substantially less than 41.9% (for
example, patients who dropout from this surveillance system can be still visiting other
physicians not in the system).
As future work, it would be important to develop double-sampling designs and methods that
can handle clinical and program constraints. For example, clinical reasons may require the
design to double-sampling all patients within a certain subgroup of patients, for example
patients who are deteriorating rapidly. In this case, e(Profilei) = 1 for patients for whom
patient characteristics suggest rapid deterioration. Here our methods could be readily
extended to select profile double-sampling within the dropouts for whom e(Profilei) ≠ 1
subject to the constraint that the double-sample already includes those for whom e(Profilei)
= 1. Additionally, it may be that double-sampling is most likely to be both successful (in
finding dropouts) and clinically beneficial when efforts are focused on patients whose time
of dropout is relatively close to “Now,” which translates to requiring that Ci – Li ≤ c for
some constant c. In this case, e(Profilei) = 0 for patients with Ci – Li > c. Our methods would
need to be carefully extended to use a likelihood that will leverage the data close to the
boundaries of the exclusion regions, using regression discontinuity [18]. If the exclusion
regions are large or at the edge of the characteristics space, the missing information can be
bounded by upper and lower bounds, as in other missing data settings, e.g., [19, 20]. Finally
we could generalize the proposed methods to address double-sampled individuals who are
not found. On the field, this problem can be limited by careful planning. At the analysis
stage, we could treat any patients still not found as censored conditionally on time-
dependent information, and then use sensitivity analyses to assess impact to the results.
PEPFAR alone is directly involved in the care of over 11 million patients affected by HIV
and AIDS. With over 20% of these expected to be lost during the first year from enrollment
[21], any effort, however well-intentioned, to locate all dropouts is doomed to fail out of
lack of resources alone. On the other hand, monitoring and evaluation of programs that
involve long-term follow-up which, in the case of PEPFAR, is required by law, cannot be
performed solely based on the observed non-dropouts [3, 8, 16]. Thus, only sampling
techniques are capable of offering means of performing meaningful evaluation of the
effectiveness of these programs. Nevertheless, we expect that our proposed designs will be
embraced by both Public Health professionals, who monitor and evaluate these programs, as
well as clinicians who are focused in improving outcomes for their patients. This is because
these designs offer the possibility of significantly reducing the resources required as fewer
individuals must be sought, which appeals to the former group, and preferentially outreach
some of the patients who are most likely to have poor clinical outcomes, which interests the
latter.
In summary, double-sampling designs are useful in using data to address possible
nonignorable dropout. The choice of a particular design set may depend on the available
staff and infrastructure of a setting. In general, profile double-sampling designs, relative to
random double-sampling designs, can help to maximize the impact of limited amounts of
resources, which is significant, particularly in resource-limited settings.
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Figure 1.
Characteristics for different patient types. The observed patient type labels correspond to those in the likelihood, described in
Section 3. Data in square brackets[ ] are only partially observed; “UD” means undefined and “NA” means not available or
missing.
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Table 1
Designs for double-sampling and resulting variance of the 1-year mortality estimate with the PEPFAR data
described in the text.
(a) Discretized double-sampling (∑k nk fixed)
Risk for dropout
low med high
Dropout time
short n 1 n 2 n 3
med n 4 n 5 n 6
long n 7 n 8 n 9
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(b) Number of people double-sampled in original design (Variance=7:1 × 10−5)
Risk for dropout
low med high
Dropout time
short 32 79 88
med 37 102 78
long 36 88 81
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(c) Number of people to double-sample for more efficient design when using ARV (Variance = 4:5 × 10−5)
Risk for dropout
low med high
Dropout time
short 121 124 15
med 0 168 193
long 0 0 0
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(d) Number of people to double-sample for more efficient design when not using ARV (Variance = 4:3 × 10−5)
Risk for dropout
low med high
Dropout time
short 127 86 26
med 0 183 199
long 0 0 0
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Table 2
1-year mortality estimates when changing the design, estimation method, and covariate specification.
design estimation method covariates used for risk index
with ART without ART
original nonparametric
estimate (%) 11.64 11.59
se (%) 0.85 0.88
lognormal MLE
estimate (%) 13.94 13.98
se (%) 0.84 0.81
predicted more efficient lognormal MLE
se (%) 0.67 0.65
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